AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
The Guardian - UK ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Gracell Biotechnologies
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
Upgrades
Benzinga ·
Preview: Gracell Biotechnologies's Earnings
Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement.
Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.21.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
The Guardian - UK
Organisations
Microsoft
24,263 stories
Nasdaq
22,789 stories
NYSE
19,900 stories
Goldman Sachs
2,763 stories
Adobe
2,208 stories
Barclays
1,841 stories
Citigroup
904 stories
NIO
891 stories
JP Morgan
754 stories
AstraZeneca
657 stories
Block
471 stories
Piper Sandler
427 stories
Snowflake
392 stories
Raymond James
285 stories
Okta
270 stories
Crocs
229 stories
Novavax
210 stories
Cisco Systems
186 stories
B of A Securities
173 stories
Zscaler
151 stories
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
